Syndrome of hyperandrogenism in girls of pubertal age

Cover Page


Syndrome of hyperandrogenism in women is one of the commonest disease of the adult age. It is associated with a high risk of metabolic disturbances, cardiovascular disorders, and infertility. Taken together, these factors dictate the necessity of in-depth investigations of this pathology. At present, both etiology and pathogenesis of the syndrome of hyperandrogenism remain obscure. As a rule, its clinical manifestations become apparent at puberty. The present review summarizes the data on the development and clinical course of female hyperandrogenism with special reference to its occurrence, diagnostic tools, and therapeutic modalities in adolescent girls.

P S Bogdanova


M A Kareva

  1. Fauser B., Eijkemans M.J. Predicting pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:9:3183-3184.
  2. Futterweit W., Nestler J., Reaven G. American Association of Clinical Endocrinologists. Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract 2005;11:2:126-134.
  3. Ching H.L., Burke V., Stuckey B.G. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol 2007;66:3:373-379.
  4. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:1:41-47.
  5. Gilling-Smith C., Willis D.S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:4:1158-1165.
  6. Kumar A., Woods K.S., Bartollucci A.A., Azziz R. Prevalence of adrenal androgen excess in patients with PCOS. Clin Endocrinol (Oxford) 2005;62:6:644-649.
  7. Mortensen M., Ehrmann D., Littlejohn E., Rosenfield R.L. Asymp­tomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab 2009;94:5:1579-1586.
  8. Hirshfeld-Cytron J., Barnes R.B., Ehrmann D.A. et al. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:5:1587-1594.
  9. Azziz R., Woods K.S., Reyna R. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:6:2745-2749.
  10. Trakakis E., Basios G., Trompoukis P. et al. An update to 21-hydroxylase deficient congenital adrenal hyperplasia. Gynecol Endocrinol 2010;26:1:63-71.
  11. Zawadsky J.K., Dunaf A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach / Polycystic ovary syndrome. Boston: Blackwell Scientific Publications 1992;377-384.
  12. ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:1:19-25.
  13. Azziz R., Carmina E., Dewailly D. et al. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete taskforse report. Fertil Steril 2009;91:2:456-488.
  14. Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
  15. Balen A., Laven J.S., Tan S.L., Dewailly D. Ultrasound assessment of polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:6:505-514.
  16. Escobar-Morreale H.F., Sanchon R., San Millan J.L. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008;93:2:527-533.
  17. Unluhizarci K., Kula M., Dundar M. et al. The prevalence of non-classic adrenal hyperplasia among Turkish women with hyperandrogenism. Gynecol Endocrinol 2010;26:2:139-143.
  18. Kuttenn F., Coullin P., Giratd F. et al. Late-onset adrenal hyperplasia in hirsutism. N Engl J Med 1985;313:4:224-231.
  19. Azziz R., Zacur H.A. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab 1989;69:3:577-584.
  20. Bidet M., Bellanne-Chantelot C., Galand-Portier M.B. et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009;94:5:1570-1578.
  21. Lutfallah H., Wang W., Mason J.I. et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002;87:6: 2611-2622.
  22. Bhattacharya S.M. Metabolic syndrome in females with polycystic ovary syndrome and international Diabetes Federation criteria. J Obstet Gynaecol Res 2008;34:1:62-66.
  23. Luque-Ramez M., Alvarez-Blasco F., Mendieta-Azcona C. et al. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:6:2141-2148.
  24. Deplewski D., Rosenfield R. Role of hormones in pilosebaceous unit development. Endocr Rev 2000;21:4:363-392.
  25. Ciaraldi T.P., Aroda V., Mudaliar S. et al. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab 2009;94:1:157-163.
  26. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:6:774-800.
  27. Shah N.A., Antoine H.J., Pall M. et al. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:5:1939-1945.
  28. Панфилова Е.В. Гормональные, метаболические и молекулярно-генетические аспекты синдрома гиперандрогении у девочек. М 2006.
  29. Paris F., Tardy V., Chalancon A. et al. Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers. Gynecol Endocrinol 2010;26:5:319-324.
  30. Cho L.W., Kilpatrick E.S., Jauagopal V. et al. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxford) 2008;68:3:390-394.
  31. Stener-Victorin E., Holm G., Labrie F. et al. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab 2010;95:2:810-819.
  32. Гончаров Н.П., Кация Г.В. Обзор литературы: Современные методы определения тестостерона. Вестн репрод здоровья 2008;1-2:31-37.
  33. Collignon I., Porquet D. Investigation of female reproductive hormone dysfunctions. Biomeieux. France. Lyon. Brochure. 2-18.
  34. Ibanez L., Dimartino-Nardi J., Potau N., Saenger P. Premature adrenarche - normal variant or forerunner of adult disease? Endocr Rev 2000;21:6:671-696.
  35. Rosenfield R.L. Clinical Review: Indentifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:3:787-796.
  36. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 2010;18:3:281-305.
  37. Петеркова В.А., Семичева Т.В. Диагностика и лечение синдрома гиперандрогении у девочек-подростков. М 2005.
  38. Fleischman A., Gordon C. Adolescent menstrual abnormalities. Pediatric Endocrinology 5th Edition. Informa Healthcare. New York (USA) 2007;2:349-360.
  39. Homburg R., Lambalk C.B. Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum Reprod 2004;19:5:1039-1042.
  40. Pasquali R., Antenucci D., Casmirri F. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:173-179.
  41. Дедов И.И., Мельниченко Г.А., Чеботникова Т.В. и др. Половое развитие детей и подростков Московского региона: влияние ожирения. Рус мед журн 2006;14:26:1872-1877.
  42. Salmi D.J., Zisser H.C., Jovanovic L. Screening for and treatment of polycystic ovary syndrome in teenagers. Exp Biol Med (Maywood) 2004;229:5:369-377.
  43. James W.D. Clinical practice. Acne. N Engl J Med 2005;352:14:1463-1472.
  44. Hoeger K.M., Davidson K., Kochman L. et al. J Clin Endocrinol Metab 2008;93:11:4299-4306.
  45. Hoeger K.M. Exercise therapy in polycystic ovary syndrome. Semin Reprod Med 2008;26:1:93-100.
  46. Ibanez L., Jaramillo A., Ferrer A., de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 2005;20:7:1833-1836.
  47. Castello-Branco C., Concelo M.J. Comprehensive clinical management of hirsutism. Gynecol Endocrinol 2010;26:7:484-493.
  48. Strauss J.S., Krowchuk D.P., Leyden J.J. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:4:651-663.
  49. de Leo V., la Marca A., Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:5:633-667.
  50. Tang T., Lord J.M., Norman R.J. et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010;1:CD003053.
  51. Ibanez L., Lopez-Bermejo A., Diaz M et al. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008;93:5:1841-1845.
  52. Glucophge. Final Printed Labeling. Centre for drug evaluation and research. Appl Number 2010;20-357:S019.


Abstract - 731




Copyright (c) 2010 Bogdanova P.S., Kareva M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies